---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-007313"
form_type: "8-K"
ticker: "ZIVO"
cik: "0001101026"
company_name: "Zivo Bioscience, Inc."
filed_at: "2022-05-20T23:59:59+00:00"
generated_at: "2026-06-25T08:32:56.048002+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zivo Bioscience updates: USDA white paper, new poultry study, licensing talks with major animal health firm

## Summary
- Submitted white paper to USDA for poultry coccidiosis product; expects jurisdiction confirmation within 8 weeks.
- Began 21st in vivo study with AH Pharma to optimize product forms and reduce production costs.
- Ongoing licensing discussions with a major animal health company; decision expected by end of Q2 2022.
- Previous 20 studies validated efficacy and mechanism of action for the lead product candidate.

## SEC filing metadata
- accession: 0001654954-22-007313
- form_type: 8-K
- ticker: ZIVO
- cik: 0001101026
- company_name: Zivo Bioscience, Inc.
- filed_at: 2022-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1101026/000165495422007313/0001654954-22-007313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1101026/000165495422007313/zivo_10q.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-007313
- JSON: https://secwatch.observer/filing/0001654954-22-007313.json
- Plain text: https://secwatch.observer/filing/0001654954-22-007313.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.